Drug Profile


Alternative Names: Alvimopan/hydrocodone/acetaminophen; Alvimopan/hydrocodone/paracetamol; Hydrocodone/acetaminophen/alvimopan

Latest Information Update: 14 Dec 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adolor Corporation
  • Developer Cubist Pharmaceuticals
  • Class Acetanilides; Gastrokinetics; Morphine derivatives; Non-opioid analgesics; Opioid analgesics; Opioid peptides; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists; Opioid receptor agonists; Prostaglandin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Pain

Most Recent Events

  • 12 Dec 2011 Adolor Corporation has been acquired and merged into Cubist Pharmaceuticals
  • 30 Jun 2006 Phase-II clinical trials in Pain in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top